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BioAtrium AG: Company overview
• Joint venture between Lonza and Sanofi, established in February 2017
• New company with its own legal entity, manufacturing license and facility
• Co-located at Lonza’s IBEX campus in Visp, Switzerland
• Shared investment/risk/capacity by Lonza and Sanofi
• Phase A: Building with 2x20kL mammalian Bioreactors, 1 DSP train
• Expected 1st Engineering batch : Q4 2020
• Phase B: Extension by 2x20kL mammalian Bioreactors, 1 DSP train
• Management by 4 persons, workforce (~380 FTE at full capacity) seconded 
by Lonza
BioAtrium AG
Ibex manufacturing complex 1
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BioAtrium: Construction site in Visp, Switzerland
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Different targets for process intensification
Different biotechnologically manufactured chemicals/products
Market demand and production scale
Selling price/manufacturing cost per kg
Degree of required process intensification
Regulatory requirements
Bulk chemicals
- citric acid
- 1,3-propane-diol
Titer >100 g L-1
STY >10 g L h-1
Cost <1 € kg-1
Specialty chemicals/products
- polymers (building blocks)
- enzymes (e.g., lipases 
esterases)
Titer 50-100 g L-1
STY 5-10 g L-1 h-1
Cost 1-10 € kg-1
Fine chemicals/products
- flavor and aroma compounds 
(e.g., menthol)
- vitamins
- nutrient additives
Titer 1-50 g L-1
STY 1 g L-1 h-1
Cost 10-100 € kg-1
Pharmaceuticals
- antibiotics
- therapeutic proteins 
(e.g., antibodies)
- erythropoietin
Titer max 5 g L-1
STY 0.1 g L-1 h-1
Cost > 100 € kg-1
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The Manufacturing Landscape
● mAb
● Fusion protein
● Bispecific antibodies
● ADC
● Orphan diseases
● Biosimilars
● Development time
● Financing (IPO, M&A)
● High titer USP
● Continuous processing
● Platform processes
● Process intensification
● Disposables
● Modular facilities
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• Combination and integration
• Requires adaptation, potentially rearrangement
• Elimination
• Biggest impact, hardest to achieve
• Simplification  
• Should always be possible
• Targeted enhancement of a phenomenon
• Cell growth, protein stability
• Uncoupling and frontloading
• Doing steps earlier and at different locations
• Can single use equipment help in that context?
What are the principles of process intensification?
• integration of operations
• integration of functions
• integration of phenomena 
Increased Decreased 
- Productivity
- Capacity
- Titer
- Flexibility  
- Complexity 
- Footprint 
- Byproducts
- Energy usage
- Waste
- Investment
- Cost
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When did disposables start in DSP?
Labscale disposable membrane chromatography for R&D
• In the early 90‘s Millipore launched the ConSep LC-100 system
• 4 sizes of MemSep cartridges with 3 surface modifications
• First FDA approved product utilizing membrane chromatography in 
2001 (Campath®)
Labscale disposable membrane chromatography for R&D
• In 1991, six types of HiTrap columns were launched 
• Today, there are over 130 different columns available
• Still focus on small scale and R&D purposes, not manufacturing 
• All columns sold in 2010, would build a chain almost 5 km long
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Wave Bioreactor
• First designed in 1996
• Smooth and gentle mixing
• High level of aeration
• Pre-sterilized and  fully disposable
When did disposables start in USP?
10
US 6190913 B1
September 26, 1996, the first Wave Bioreactor
Singh, V. The Wave Bioreactor Story (2005)  
Stefan Schmidt  |  BioAtrium AG  |  23 September 2018 11
Benefits and Limits of Disposables (CMO Perspective)
Quality
Supplier qualification
Flexibility
Transportation risk
Standardization
Scale limitation
Customization
Supplier dependency
SafetyLeachables & extractables
Lower cross contamination
Fully closed process
Particulates
Sterilization
Leakage
Waste management
Cost
Lower investment
Smaller footprint
Reduced complexity
Lower maintenance
Storage space
Repetitive consumables
Supplier monopoly
Inventory
Time
Faster installation
Faster changeoverDelivery lead times
Shelf live
Faster time to market
Schmidt, S. R. The Benefits and Limits of Disposable Technologies in Manufacturing Protein Therapeutics. Am. Pharm. Rev. 19, 60–62 (2016).
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How can a biopharmaceutical process be intensified?
Levine, HL. et al. Single-Use Technology and Modular Construction. Enabling Biopharmaceutical Facilities of the Future. Bioprocess Int. 11(4), p40-45, (2013).
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Overview of approaches
USP: Strategies for process intensification
Number of seed 
train steps
Inoculum cell 
density
Type of 
clarification
Number of 
clarification steps
Media 
optimization
Type of 
seed train
Production 
conditions
Process 
development
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Automation and miniaturization 
• HTS-approach for process optimization including DoE capabilities
• Ambr® 250: good control and high capacity with short turnaround 
• 24 individual bioreactors with automated sampling
• Process adjustment/optimization with predictable scale-up 
• Scale-down approaches:
• volumetric power input variation
• gassing strategy
• feeding volumes in triplicates
• Significant cost and labor reduction
USP process development
Cost
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Inoculum cell density & volume
Sargent B., Direct inoculum of bioreactors with CHO cells from frozen seed bags to eliminate continual seed trains and improve facility utilization. Cell Culture Dish. January 24, (2017)
• Inoculum: 30-400 mL of cells at 20-50 M cells/mL in 7-10 days perfusion 
• Tubing and containers
• cryogenic storage and transport validated to -196°C
• storage in metal freezing cassettes
• compatible with sterile tube welder 
• Closed process by aseptic transfer via tube-to-tube connection
• Reduces handling, contamination risk and seed train expansion steps
• DMSO concentration is critical
• 2-3 fold faster from inoculum to bioreactor
FP-FLEX™
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Seedtrain
USP intensification
Perfusion process  Fed-batch process
Wright, B. et al. A novel seed-train process: Using high-density cell banking, a disposable bioreactor, and perfusion technologies. Bioprocess Int. 13(3), p16-25, (2015).
Benefits
• Process time savings
• Hands-on time reduction
• Process safety increase
• Less equipment
• Smaller footprint
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• Up to 2 batches more produced per 
year through higher plant utilization
• About 60 m2 reduction in facility 
footprint with fewer bioreactors
• About 40% reduction of labor cost for 
seed preparation
• Between 10% and 20% reduction in 
upstream production cost 
• Highest cost savings with small volume 
products with few batches per year
Benefits from seed train intensification
© Courtesy of GE-Lifesciences
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• Higher inoculation VCD through perfusion in N-1
• At end of N-1: density >40 × 106 cells/mL 
• 30% increase in manufacturing capacity (5 days shorter process) 
• Comparable product quality and yield
• Shorter cultivation time may even result in less degraded product
• Alternatively, if cells maintain high viability more product is generated at 
original cultivation time  impacting DSP dimensions
Time savings in main reactor
Process simulation based on traditional N-1 step 
Process simulation based on perfusion in N-1 step 
Yang, W. C. et al. Perfusion seed cultures improve biopharmaceutical fed-batch production capacity and product quality. Biotechnol. Prog. 30, 616–625 (2014).
Higher cell density
5 days time gain
Drivers:
• Higher cell density 
• Longer process time
• Genetic engineering
• Metabolic engineering 
• Improved media
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High titer processes and culture media
BioPlan 15th Annual Biomanufacturing Report, p 193, (2018)
Reinhart, D. et al. Benchmarking of commercially available CHO cell culture media for antibody production. Appl Microbiol Biotechnol. 99(11), p4645-4657, (2015)
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pH 5.0 experiments with Celpure C300 with best performance:
• Filtration capacity (size of filter)
• Flux (duration of run)
• Impurity removal (HCP, DNA) 
• Fast process: harvest of 600 L in 1 h with 7 DF modules
• Scalable to 3000L with 33 DF modules in same time
Harvest clarification: Depth filtration with Diatomaceous Earth
Minow, B. et al. High–Cell-Density Clarification By Single-Use Diatomaceous Earth Filtration. Bioprocess Int. 12(4), p16-46, (2014).
Schmidt, SR. et al. Single-Use Depth Filters Application in Clarifying Industrial Cell Cultures. Bioprocess Int. 14(1), p6-11, (2017).
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Scale and flow limitations vs time savings and lower contamination risk
• Single-use devices: 
• kSep-Systems (up to 2000xg, 720 L h-1)
• ATF 10 single use (exchange rate up to 3600 L h-1)
• Unifuge – Pneumatic Scale Angelus (up to 4000xg, 240 L h-1)
Cell Removal/Retention with Disposable Systems
* Pictures are courtesy of Sartorius, Repligen and PSA
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Overview of approaches
DSP: Strategies for process intensification
Single Pass 
TFF
Mixed 
mode resins
Buffer 
management
Combination 
of filter steps
Precipitation 
of impurities
FT membrane 
chromatography
Freezing 
in bags
PAT and 
sensors
© Sartorius
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General strategies reducing cost, time and footprint
Buffer management
© ILC Dover
© Argon medical devices
Generic buffers (recipes)
Reduce number of buffers and all subsequent efforts
Pre-dispensed buffer substances in bags
Ready to use, eliminate own preparation, closed system
Buffer prep in disposable mixtainers
Faster change-over, no cleaning
Robotic transfer of filled bags
Eliminate non- value adding work, enable traceability
Multi-bag concept
Optimal usage of buffer volumes
Inline blending/dilution based on (concentrated) stock solutions
Optimal volume utilization
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Generic buffers for DSP in a model mAb process
EQ W1 W2 EL RE CIP SIP
EQ W ELRE CIP SIP
EQ W ELRE CIP SIP
A10
B90
A30
B70
A70
B30
RE
CIP
SIP
Generic: 5 buffers
ProA CIEX AIEC
• Advantages
• Less buffer definitions
• Logistics: less transport and storage efforts
• Costs: utilizable in more projects
Traditionally: 13 buffers
ProA CIEX AIEC
© Courtesy of Rentschler Biopharma SE
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Concept of multi-bag buffer supply
Buffer bag
Air sensor
Valve 
block
Mouse 
hole
Sterile 
connector
Pump
Column
Drain
CNC                                                                         Cleanroom
• No open handling, sterile connectors
• Buffer handling outside of cleanroom
• Tagged bags eliminating confusion
• Multi batch usage if hold times allow it
• Standardization of volumes enabled
• Reduced backup volume required
• Max. volume utilization (complete drain of bag)
• Eliminate drain need when discarding bags
• Automated switch when air passes
• Valve block to divert from different sources
• Tubing is washed and primed by skid-pump
• No CIP/SIP required
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Requires dynamic control of pH and conductivity
Buffer dilution and blending
Principle
Description
Controlling
probes
Monitoring 
probes
Benefits
Water
Buffers
Fabbrini, D., et al. Addressing the Challenge of Complex Buffer Management. Bioprocess Int. 15, 43–46 (2017).
Increased complexity
Recipe and flow
Buffer formulated 
using recipe
Flowmeters 
pH, conductivity, 
flowmeters
Robust at constant 
T and accurate 
stock solutions
pH and flow
Buffer formulated 
based on target pH
and concentration
pH and flowmeters
pH, conductivity, 
flowmeters
Delivers correct pH 
and concentration 
even if temperature 
varies
pH and conductivity
Buffer formulated 
based on target pH
and conductivity
pH, conductivity, 
flowmeters
pH, conductivity, 
flowmeters
When variability in 
stock solution is 
expected, delivers 
correct pH and 
conductivity even if 
T varies
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• Adjust flow to minimum residence time of 
60 min.
• Titrating solution must be buffered to 
avoid pH fluctuations.
• Provide efficient radial and minimal axial 
mixing to ensure >99% liquid exits in <3 h.
• Enable validation for GMP use
Advantages:
• Easy scalable
• High reproducibility
• Sterilizable single-use material
• Inexpensive manufacture by molding or 3D 
printing.
Continuous acidic pH virus inactivation
Orozco, R. et al. Design, construction, and optimization of a novel, modular, and scalable incubation chamber for continuous viral inactivation. Biotechnol. Prog. 33, 954–965 (2017).
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Eliminating time for packing and qualification
Pre-packed columns
Brand Opus RTP Chromabolt CIMmultus EvolveD
Company Repligen GE-Lifesciences Merck/Millipore Bia Separations Prometic
Diameter [cm] 10-80 8-45 10-32 7/10/20
Bedheight [cm] 5-40 20 20 10 or 20
Volume [L] 0.5 - 150 0.8 - 32 1.6 - 16.1 0.001 - 8 0.38 - 6
Pressure [bar] 3 4 3.5 14 4
Resins all own own own (monolithic) own
Design
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Combination of multiple separation methods in one step
Capto Core 700: both size exclusion and IEX/HIC binding properties
• Efficient capture of contaminants, target molecules in the flow through
• Improved productivity and higher flow rates (compared SEC) 
• Easy optimization due to flow through chromatography and robust 
performance
Capto MMC: fourfold functionality
• Bind elute with conductivity, pH, hydrophobicity
• Potential of FT chromatography
• Simultaneous enrichment of product while removal of impurities
Mixed mode chromatography
Zhang, K. et al. Mixed-mode chromatography in pharmaceutical and biopharmaceutical applications. J Pharm and Biomed Anal. 128, p73-88, (2016). 
Hydrophobicity
HIC
HIC
Charges
IEX
IEX
Thiophilic
H-pairing
Functionality:
Tetra-
Dual-
Triple-
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Concentration 
• SPTFF eliminates the conventional TFF recirculation loop 
• Concentrated retentate of the TFF device loads directly onto the column. 
• The lower volumes and higher titers decrease loading time, reducing tubing and equipment sizes
• Reduced volumes also enable the utilization of disposable, single-use technologies
• Concentration factors of 2 to 30X
Single pass TFF (SPTFF)
Casey, C., et al. Cadence™ Single-pass TFF Coupled with Chromatography Steps Enables Continuous Bioprocessing while Reducing Processing Times and Volumes. American Pharm. Rev. (2016)
Development parameter
• Cross flow rate
• Number of sections (serial)
• Membrane area per section
• Serial vs parallel
VCF: volumetric concentration factor
© Pall
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Diafiltration
• Repeated dilution and concentration without recirculation
• Product concentration impacts feed pressure profile
• 3 log removal (99.9 %) requires 13 DF in SPTFF versus 7 DF conventionally
SPTFF or ILDF (Inline diafiltration) 
ILDF
Reference
Conventional
© Pall
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• Larger pores, negligible diffusion time, higher flow rates
• Available as disposable module 
• Sufficient capacity in FT mode, only binding of impurities (HCP, DNA)
Membrane chromatography in FT mode
Gupte, P., et al. Establishing Effective High-Throughput Contaminant Removal with Membrane Chromatography. Bioprocess Int. 16(1-2), p60-63, (2018).
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Functionalized (positively charged) filters
Advantages
• Higher flow rate
• Reduced process time
• Lower buffer consumption
• Disposable membrane
• Integration of virus and HCP reduction
Combination of impurity elimination and virus removal in depth filtration
Trapp, A. et al. Evaluating adsorptive filtration as a unit operation for virus removal. Bioprocess Int. 16, p58–62 (2018).
PG: propylene glycol
• Virus-Reduction Filtration: variations in temperature can affect 
the polymeric structure of the filter or the mechanism of virus 
retention.
• Final Ultrafiltration: this operation often is the final conductivity 
measurement of a drug product before it enters a vial.
• Sterilization: the validated cross-filter pressure drop must not be 
exceeded to prevent breakthrough
• Ideally all sensors used for monitoring can also actively regulate 
the measured parameter by automation:
• Flowrate reduction when pressure builds up
• Extending dia-filtration time and volume if conductivity is not 
reached
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Increasing safety and process performance
Disposable sensors in critical unit operations
Hutchinson, N. Understanding and Controlling Sources of Process Variation. Bioprocess Int. 12, 24–29 (2014)
• Fully automated & closed fill/drain system of single-use bags
• Filling up to 200 L bulk drug substance in < 1 hour
• Accuracy +/-10 mL for 10 L with single weight cells
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Faster, less effort, better control, lower risk, smaller footprint
Automated final fill of bulk drug substance
www.susupport.com Hutchinson, N. Understanding and Controlling Sources of Process Variation. Bioprocess Int. 12, 24–29 (2014)
• Automated fill in bottles, fully disposable closed flow path
• Standardization of operations, less variability and manual 
interference
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Freezing in bags
• Plate-based freeze-thaw unit
• 1 L- 10 L nominal filling volume, 
maximum capacity 240 L
• Shell required for transport and storage
• Any volume possible
www.susupport.com
• Isolating air layer in head space of the
bottle and to the freezer 
• Large layer thickness in the bottles
• Freeze/thaw time approx. 20h. 
• Large contact area to plate freezer
• Small layer thickness fast and gentle
• Freeze & thaw time approx. 3h.
• Critical zone in bags where different
plastics come together
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A cost of goods perspective
• 1 kg of purified mAb every 4 days (in a 30 days campaign) from a 200L SUB
• 15% cost reduction at 30 day campaign 
• Approximately 50% lower capital investment
• Small columns 10–11 cycles/d, lifetime reached in 3 weeks 
• Small surge tanks only used for pressure relief, no need of large pool tanks
Process intensification and continuous processing
Arnold, L., et al. Implementation of Fully Integrated Continuous Antibody Processing: Effects on Productivity and COGm. Biotech J., (2018)
fed-batch with 4 x 12 500 L SS bioreactors continuous facility 5 x 2000 L SUB
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Univercells modular concept
Concept
• Increased integration  footprint reduction
• Minimal infrastructure due to single use
• Cost-effective modular production of biologics 
• Small to medium-size markets
Upstream
• Suspension or fixed-bed single-use bioreactors
• Fed-batch or perfusion mode
Downstream
• Proprietary innovative clarification technology
• Integrated SMB purification
Cost driven integration of manufacturing
Jacquemart, R. et al. A Single-use Strategy to Enable Manufacturing of Affordable Biologics. Comput. Struct. Biotechnol. J. 14, 309–318 (2016).
© Univercells
USP     DSP
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Specific demand for cell therapy manufacturing in close proximity to hospitals
Megatrend personalized medicine
© Phrma
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Integrated systems
• Cell therapies as next generation treatments
• Autologous  allogeneic 
• Lot size 1 (patient), small volume
• Proximity to patients in hospitals
• No need for re-use
• No DSP processing required
Cocoon™:
• High level of system integration, fully encapsulated
• Cell isolation, washing, expansion and formulation
• Reduced need for GMP facility environment
• Cells are refunded back into patient
Trend towards personalized medicine I
Octane Cocoon™ cell production platform for personalized cell therapy manufacturing
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Quantum®
• Single use bioreactor (11,500 hollow fibers with a surface 
area of 2.1 m2)
• Expands adherent cells (e.g. mesenchymal stem cells)
• Fully closed, automated, GMP compliant
• Continuous temperature control, cell feeding and waste 
removal 
• Small footprint, direct installation in hospital possible
Trend towards personalized medicine II
Hanley, P. J. et al. Efficient manufacturing of therapeutic mesenchymal stromal cells with the use of the Quantum Cell Expansion System. Cytotherapy 16, 1048–1058 (2014).
Quantum® automated adherent cell expansion system by TerumoBCT
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Technology combining multiple operations into one automated platform
Autologous Cell therapy
Counterflow Centrifuge Device (CFC): Invetec & Caladrius Biosciences
• Concentration/volume reduction
• Cell washing
• Media exchange
• Particle depletion
• Short-term incubation
System components
• Instrumentation platform,
• Novel disposable flow path
• Operating and application software for automated execution of 
user-selected protocols
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Manufacturing automation equipment platforms for allogeneic cell therapy development
System components include:
• Four, 100-layer cell culture containers
• Cell expansion platform to handle 
expansion containers and medium 
fluidics
• Formulation platform for automated, 
closed, accurate and rapid formulation 
of concentrated cell suspension with 
cryo-preservative
• WCB dispensing platform, enabling 
automated, closed, cryo-bag filling for 
up to 100 bags
• Large populations of adherent cells in 
multiple parallel containers as a single 
batch
Human umbilical tissue-derived cells (hUTCs) therapies
© Invetec
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Summary
• Cell banking in bags
• Seed train in SUB or Wave
• Perfusion at N-1 step using ATF
• Continuous virus inactivation
• Single use based buffer management
• Prepacked columns of different variations
• Concentration by SPTFF
• Flow-through steps and membrane cartridges
• Mixed mode single use virus filter
• Online monitoring with single use sensors
• Final fill in bags
Technical approaches with disposables
De Vries W., European roadmap to process intensification: https://www.rvo.nl/sites/default/files/bijlagen/European_Roadmap_Process_Intensification.pdf
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• Process intensification can be implemented in most processes but should be evaluated already during development
• In USP the highest efficiency gain by improving the seed/inoculation train and a step elimination strategy
• Process intensification in DSP allows more options (resins, membranes, procedures, etc.)
• The biggest benefit in DSP by combining operations (precipitation, mixed mode resins, SPTFF and chromatography)
• Disposables have a huge impact on intensification by eliminating labor and preparation time
• Continuous processing is easiest established in the USP but new DSP approaches support end to end continuous processes
• Personalized medicine can significantly benefit from integrated intensified processes based on disposable elements
Summary
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Thanks - Questions?
